A recently discovered mechanism enabling prostate cancer cells to escape the effects of endocrine therapies consists in the synthesis of C-terminally truncated, constitutively active androgen receptor (AR) splice variants (AR-V). Devoid of a functional C-terminal hormone/ligand binding domain, various AR-Vs are insensitive to therapies targeting the androgen/AR signalling axis. Preliminary studies suggest that AR-V7, the most common AR-V, is a promising predictive tumour marker and a relevant selection marker for the treatment of advanced prostate cancer. This review critically outlines recent advances in AR-V7 diagnostics and presents an overview of current AR-V7 targeted therapies.
|Translated title of the contribution||The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer|
|Number of pages||11|
|Publication status||Published - 2020|
Research Areas and Centers
- Centers: University Cancer Center Schleswig-Holstein (UCCSH)